$5.72
1.38% today
Nasdaq, Aug 04, 04:54 pm CET
ISIN
US92511W1080
Symbol
VRCA

Verrica Pharmaceuticals Inc Stock price

$5.64
-0.37 6.16% 1M
-0.77 12.03% 6M
-1.36 19.43% YTD
-57.66 91.09% 1Y
-23.86 80.88% 3Y
-59.16 91.30% 5Y
-169.36 96.78% 10Y
-169.36 96.78% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.01 0.18%
ISIN
US92511W1080
Symbol
VRCA
Industry

Key metrics

Basic
Market capitalization
$52.2m
Enterprise Value
$64.2m
Net debt
$12.0m
Cash
$29.6m
Shares outstanding
9.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.3 | 2.6
EV/Sales
8.9 | 3.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-18.2%
Return on Equity
776.7%
ROCE
-433.9%
ROIC
-
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$7.2m | $20.1m
EBITDA
$-54.2m | $-31.5m
EBIT
$-55.5m | $-22.9m
Net Income
$-66.0m | $-2.7m
Free Cash Flow
$-53.7m
Growth (TTM | estimate)
Revenue
-19.4% | 165.1%
EBITDA
29.2% | 51.2%
EBIT
28.2% | 65.3%
Net Income
18.3% | 96.4%
Free Cash Flow
1.2%
Margin (TTM | estimate)
Gross
71.6%
EBITDA
-755.5% | -157.1%
EBIT
-772.4%
Net
-919.2% | -13.6%
Free Cash Flow
-747.4%
More
EPS
$-7.0
FCF per Share
$-5.8
Short interest
4.3%
Employees
71
Rev per Employee
$110.0k
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
64%
Hold
36%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.18 7.18
19% 19%
100%
- Direct Costs 2.04 2.04
12% 12%
28%
5.14 5.14
28% 28%
72%
- Selling and Administrative Expenses 51 51
13% 13%
715%
- Research and Development Expense 9.18 9.18
59% 59%
128%
-54 -54
29% 29%
-755%
- Depreciation and Amortization 1.21 1.21
78% 78%
17%
EBIT (Operating Income) EBIT -55 -55
28% 28%
-772%
Net Profit -66 -66
18% 18%
-919%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
26 days ago
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH ® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....
Neutral
GlobeNewsWire
about one month ago
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule –
Neutral
GlobeNewsWire
2 months ago
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Co...
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Jayson Rieger
Employees 71
Founded 2013
Website verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today